NCT02249676View on ClinicalTrials.gov

Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Devic's SyndromeDevic's Neuromyelitis OpticaDevic SyndromeDevic's DiseaseDevic Disease
Interventions
BIOLOGICAL

Autologous mesenchymal stem cells

Autologous mesenchymal stem cells

Trial Locations (1)

300052

Tianjin Medical University General Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University General Hospital

OTHER

NCT02249676 - Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders | Biotech Hunter | Biotech Hunter